Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Clinical trial NCT00290771 · TERMINATED

Trial details

NCT number: NCT00290771
Sponsor: Novartis
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Glioblastoma Multiforme (GBM)

Start date: 2006-02-01
Primary completion: 2008-08-01
Enrollment: 231

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.